CagriSema vs Zepbound: What the Trial Data Suggests

CagriSema and Zepbound are two of the most powerful weight-loss approaches in obesity medicine, and on trial data they land in a broadly similar range: CagriSema produced average weight loss of about 20% in its main study, while Zepbound (tirzepatide) produced about 20% to 22% in its pivotal trial. The practical difference right now is availability. Zepbound is FDA approved and on the market, while CagriSema is still investigational and awaiting an FDA decision expected in late 2026. So while their numbers are comparable, only one of them is something you can actually start today.

Two different mechanisms, similar results

These drugs reach comparable weight loss through different biology.

Zepbound contains tirzepatide, a dual agonist that activates GLP-1 and GIP receptors. Both are gut hormones involved in appetite and blood sugar regulation, and combining them has proven highly effective.

CagriSema pairs semaglutide (a GLP-1 drug) with cagrilintide (an amylin analog). Instead of adding GIP, it adds amylin, a different appetite-regulating hormone. It’s a reminder that there’s more than one way to reach strong weight loss.

Weight loss compared

Zepbound’s benchmark comes from its pivotal obesity trial published in the New England Journal of Medicine in 2022, where tirzepatide produced average weight loss of up to about 21% at the highest dose over 72 weeks. CagriSema’s main trial reported about 20% over 68 weeks, with 60% of participants losing at least 20% of their body weight.

Because there’s no head-to-head trial, comparing across separate studies has real limits. Different trial populations, durations, and statistical methods make small differences hard to interpret. The honest takeaway is that both produce weight loss in the highest range seen with medications, and neither has clearly established superiority over the other.

Side effects

Both share the GLP-1 class side effect profile, with gastrointestinal effects like nausea, constipation, and diarrhea being most common and generally mild to moderate, especially during dose escalation. Neither combination appears to introduce a dramatically different safety picture, though the full profile of CagriSema will keep coming into focus as its program reports.

The deciding factor: availability

Consider a hypothetical patient comparing the two. On paper, she might find the numbers nearly a wash. But Zepbound is approved and prescribable now, with real-world use behind it, while CagriSema can’t be prescribed until the FDA acts. For anyone making a decision this year, that difference outweighs a percentage point or two of trial weight loss.

Common questions

Is CagriSema stronger than Zepbound?

The trial numbers are similar, and without a head-to-head study, no one can say one is definitively stronger. Both are among the most effective options studied.

Can I get CagriSema instead of Zepbound?

Not yet. CagriSema is investigational and awaiting FDA review. Zepbound is available now.

Which has fewer side effects?

Both have a similar class-based profile. Individual tolerability varies from person to person, which is part of why provider guidance matters.

The bottom line

CagriSema and Zepbound look comparable on trial weight loss, but Zepbound has the practical edge of being approved and available today. If you’re deciding now, the realistic comparison favors what you can actually start. You can compare your options with a provider through TrimRx’s quiz and find out what fits your situation.

This information is for educational purposes and is not medical advice. CagriSema is investigational and not FDA approved. Consult a healthcare provider before starting any medication. Individual results may vary.